Estrella Immunopharma Inc. has announced the closing of an $8.0 million registered direct offering and a concurrent private placement with a single healthcare-focused institutional investor. As part of the transaction, the company issued 4,063,290 shares of common stock and 1,000,000 pre-funded warrants. In the concurrent private placement, Estrella Immunopharma also issued common warrants to purchase up to an aggregate of 7,594,935 shares of common stock. The company has agreed to file one or more registration statements with the SEC to cover the resale of the shares of common stock issuable upon exercise of the common warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106009556) on January 06, 2026, and is solely responsible for the information contained therein.